Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580235 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2USP2KDM4EALPLTSHR | |
| SCHEMBL29580196 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2USP2KDM4EALPLTSHR | |
| SCHEMBL10498551 | 0.83 | TRPV4 (0.53) | SMN1; SMN2KDM4EALPLTSHRALDH1A1 | |
| SCHEMBL24314192 | 0.83 | TRPV4 (0.50) | SMN1; SMN2USP2KDM4EALPLTSHR | |
| SCHEMBL1127669 | 0.80 | KDM4E (0.59) | SMN1; SMN2USP2KDM4EALPLTSHR | |
| SCHEMBL10786166 | 0.77 | MAPT (0.47) | SMN1; SMN2TSHRALDH1A1HTTS1PR4 | |
| SCHEMBL8868136 | 0.77 | L3MBTL1 (0.46) | SMN1; SMN2KDM4EALDH1A1TRPV4POLB | |
| SCHEMBL28867499 | 0.77 | L3MBTL1 (0.46) | SMN1; SMN2KDM4EALDH1A1TRPV4POLB | |
| SCHEMBL30013871 | 0.76 | S1PR4 (0.53) | SMN1; SMN2USP2ALDH1A1S1PR4POLB | |
| SCHEMBL3980436 | 0.76 | S1PR4 (0.53) | SMN1; SMN2USP2ALDH1A1S1PR4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3559007-B1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO CO LTD (JP) | 2023-08-16 | — | — | EP | disclosed |
| CN-110167946-B | Sulfonamide compounds having TNAP inhibitory activity | 第一三共株式会社 | 2022-04-08 | — | — | CN | disclosed |
| US-11046710-B2 | Sulfonamide compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11014939-B2 | — | — | 2021-05-25 | — | — | US | disclosed |
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-03-19 | — | — | US | disclosed |
| EP-3559007-A1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018119444-A1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | ALPI, ASAH2, STS | SMN1; SMN2 2383/4885USP2 3342/4885KDM4E 1553/4885 |
| US-11014939-B2 | — | ALPI, ALPP, ACER2 | SMN1; SMN2 3344/4885USP2 4055/4885KDM4E 1655/4885 |
| US-11046710-B2 | Sulfonamide compounds | ALPI, ASAH2, STS | SMN1; SMN2 2383/4885USP2 3342/4885KDM4E 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.